{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:56Z","timestamp":1788401636209,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pregnant individuals are at increased risk of severe COVID-19-related morbidity and adverse obstetric outcomes, highlighting the importance of effective vaccination. Although COVID-19 vaccine safety during pregnancy is well established, real-world evidence on vaccine-induced humoral immunity remains limited. This study compared neutralizing antibody responses after COVID-19 vaccination in pregnant and non-pregnant women and evaluated the effects of vaccine dose number, platform, and timing during pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study included 171 vaccinated women of reproductive age, comprising 95 pregnant and 76 non-pregnant participants. Neutralizing antibody titers were measured using a surrogate virus neutralization test. Vaccine platforms included mRNA vaccines (BNT162b2, Pfizer\u2013BioNTech), inactivated vaccines (CoronaVac, Sinovac), and a small number of heterologous regimens. Antibody levels were compared using the Mann\u2013Whitney\n                      <jats:italic>U<\/jats:italic>\n                      test. Associations between antibody titers and vaccine dose number, age, gestational age, and trimester were assessed using Spearman correlation analyses and Jonckheere\u2013Terpstra trend tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pregnant women had significantly lower neutralizing antibody titers than non-pregnant controls (median 5.62 vs. 16.25\u202fAU\/mL;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.008) and were less likely to reach the assay\u2019s upper detection limit (\u226530\u202fAU\/mL: 18.9% vs. 43.4%). Although the categorical distribution of vaccine dose counts was broadly similar between groups (\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.098), the mean number of doses was significantly lower among pregnant women (1.93\u202f\u00b1\u202f0.72 vs. 2.32\u202f\u00b1\u202f1.02;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.011), reflecting differences in cumulative vaccine exposure at higher dose levels. Antibody titers were strongly associated with vaccine dose number overall (\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u202f=\u202f0.341,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001) and in both pregnant and non-pregnant women. When stratified by dose category, antibody titers did not differ by pregnancy status. Gestational age and trimester were not independently associated with antibody levels, although the dose\u2013response relationship was strongest in second-trimester vaccination. In unadjusted comparisons, mRNA vaccines were associated with numerically higher titers than inactivated vaccines (median 11.30 vs. 7.72\u202fAU\/mL;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.165). mRNA platform was also independently associated with higher titers in multivariable analysis (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u202f=\u202f0.721,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.030); this finding should be interpreted cautiously given the small inactivated-vaccine subgroup (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f18).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>COVID-19 vaccination elicits robust neutralizing antibody responses in pregnant women, with overall humoral responsiveness preserved despite quantitative differences in antibody magnitude. Lower antibody levels are predominantly explained by differences in cumulative vaccine exposure rather than pregnancy-related immune impairment, although a residual independent association of pregnancy cannot be fully excluded. Completing recommended vaccine schedules is essential to optimize maternal and neonatal protection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1778064","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:43:14Z","timestamp":1778823794000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative immunogenicity of COVID-19 vaccination in pregnant and non-pregnant women: a real-world cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Altan","family":"Aksoy","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Ankara Training and Research Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015feg\u00fcl","family":"Karahano\u011flu","sequence":"additional","affiliation":[{"name":"Clinic of Obstetrics and Gynecology, Ankara Training and Research Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih","family":"Cesur","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukiye","family":"Berkem","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Ankara Training and Research Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe Esra","family":"Karako\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Ankara Training and Research Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"\u00dcst\u00fcn","sequence":"additional","affiliation":[{"name":"Clinic of Obstetrics and Gynecology, Ankara Training and Research Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"K\u0131n\u0131kl\u0131","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Emin","family":"Demir","sequence":"additional","affiliation":[{"name":"School of Medicine, Medicana International Ankara Hospital, At\u0131l\u0131m University","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"303.e1","DOI":"10.1016\/j.ajog.2021.03.023","article-title":"Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study","volume":"225","author":"Gray","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.2021.7563","article-title":"Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women","volume":"325","author":"Collier","year":"2021","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.15585\/mmwr.mm6944e3","article-title":"Characteristics of symptomatic women with laboratory-confirmed SARS-CoV-2 infection by pregnancy status","volume":"69","author":"Zambrano","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/AOG.0000000000004339","article-title":"Disease severity and perinatal outcomes in pregnant patients with COVID-19","volume":"137","author":"Metz","year":"2021","journal-title":"Obstet Gynecol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.15585\/mmwr.mm7047e1","article-title":"Risk for stillbirth among women with and without COVID-19 at delivery hospitalization\u2014United States, March 2020\u2013September 2021","volume":"70","author":"DeSisto","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"68.e1","DOI":"10.1016\/j.ajog.2022.07.014","article-title":"COVID-19 booster dose induces robust antibody response in pregnant, lactating, and nonpregnant women","volume":"228","author":"Atyeo","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1016\/j.vaccine.2023.03.038","article-title":"Safety of COVID-19 vaccines during pregnancy: a systematic review and meta-analysis","volume":"41","author":"Ciapponi","year":"2023","journal-title":"Vaccine"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41577-021-00525-y","article-title":"Are COVID-19 vaccines safe in pregnancy?","volume":"21","author":"Male","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.2147\/IJWH.S548444","article-title":"Maternal and neonatal outcomes in pregnant women vaccinated against COVID-19 compared to an unvaccinated group","volume":"17","author":"Nourian","year":"2025","journal-title":"Int J Womens Health"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/vaccines12030289","article-title":"Pregnancy outcomes among pregnant persons after COVID-19 vaccination: assessing vaccine safety in retrospective cohort analysis of U.S. National COVID Cohort Collaborative (N3C)","volume":"12","author":"Faherty","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/ijgo.14336","article-title":"COVID-19 vaccine and pregnancy outcomes: a systematic review and meta-analysis","volume":"159","author":"Carbone","year":"2022","journal-title":"Int J Gynaecol Obstet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.molmed.2022.04.012","article-title":"COVID-19 vaccines in pregnancy","volume":"28","author":"Nunes","year":"2022","journal-title":"Trends Mol Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1016\/j.vaccine.2023.06.032","article-title":"COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn","volume":"41","author":"Munoz","year":"2023","journal-title":"Vaccine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3390\/ijms25042031","article-title":"T cell responses in pregnant women after mRNA COVID-19 vaccination","volume":"25","author":"Chambers","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-025-02437-y","article-title":"Neutralizing antibody durability after XBB-containing vaccine booster","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"106362","DOI":"10.1016\/j.jinf.2024.106362","article-title":"Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination","volume":"89","author":"Jia","year":"2024","journal-title":"J Infect"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2589-7500(23)00093-6","article-title":"Effect of COVID-19 vaccination and booster on maternal-fetal outcomes: a retrospective cohort study","volume":"5","author":"Piekos","year":"2023","journal-title":"Lancet Digit Health"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1778064\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:43:17Z","timestamp":1778823797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1778064\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":17,"alternative-id":["10.3389\/fpubh.2026.1778064"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1778064","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1778064"}}